Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors (MANTRA-2)

Trial Profile

A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors (MANTRA-2)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Milademetan (Primary)
  • Indications Adenocarcinoma; Adrenocortical carcinoma; Advanced breast cancer; Biliary cancer; Bladder cancer; Cancer; Cervical cancer; Cholangiocarcinoma; Gastric cancer; Head and neck cancer; Lung cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Sarcoma; Solid tumours; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms MANTRA-2
  • Sponsors Rain Oncology
  • Most Recent Events

    • 16 Oct 2023 Status changed from suspended to discontinued as per sponsor decision.
    • 10 Aug 2023 According to a Rain Therapeutics media release, submitted abstracts to upcoming medical conferences; anticipate presentations in 4Q 2023.
    • 10 Aug 2023 According to a Rain Oncology media release, suspended enrollment in May 2023 and trial will be discontinued in 4Q 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top